Search Results - Karim Iskander

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes

    Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes by Ola Landgren, Karim Iskander

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    NRH:Quinone Oxidoreductase 2 and NAD(P)H:Quinone Oxidoreductase 1 Protect Tumor Suppressor p53 against 20S Proteasomal Degradation Leading to Stabilization and Activation of p53

    NRH:Quinone Oxidoreductase 2 and NAD(P)H:Quinone Oxidoreductase 1 Protect Tumor Suppressor p53 against 20S Proteasomal Degradation Leading to Stabilization and Activation of p53 by Xing Gong, Labanyamoy Kole, Karim Iskander, Anil K. Jaiswal

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    NQO1 and NQO2 Regulation of Humoral Immunity and Autoimmunity

    NQO1 and NQO2 Regulation of Humoral Immunity and Autoimmunity by Karim Iskander, Jessica Li, Shuhua Han, Biao Zheng, Anil K. Jaiswal

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma

    Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma by Ola Landgren, Pieter Sonneveld, Andrzej Jakubowiak, Mohamad Mohty, Karim Iskander, Khalid Mezzi, David S. Siegel

    Published 2019
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Disruption of Dihydronicotinamide Riboside:Quinone Oxidoreductase 2 (NQO2) Leads to Myeloid Hyperplasia of Bone Marrow and Decreased Sensitivity to Menadione Toxicity

    Disruption of Dihydronicotinamide Riboside:Quinone Oxidoreductase 2 (NQO2) Leads to Myeloid Hyperplasia of Bone Marrow and Decreased Sensitivity to Menadione Toxicity by Delwin J. Long, Karim Iskander, Amos Gaikwad, Meral J. Arin, Dennis R. Roop, Richard J. Knox, Roberto Barrios, Anil K. Jaiswal

    Published 2002
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types

    The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types by Hermann Einsele, Hossein Borghaei, Robert Z. Orlowski, Marion Subklewe, Gail J. Roboz, Gerhard Zugmaier, Peter Kufer, Karim Iskander, Hagop M. Kantarjian

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR

    Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR by Meletios Α. Dimopoulos, David S. Siegel, Darrell White, Ralph V. Boccia, Karim Iskander, Zhao Yang, Amy Kimball, Khalid Mezzi, Heinz Ludwig, Rubén Niesvizky

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials

    Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials by Ajai Chari, A. Keith Stewart, Stuart D. Russell, Philippe Moreau, Joerg Herrmann, José Banchs, Roman Hájek, John D. Groarke, Alexander R. Lyon, George N. Batty, Sunhee Ro, Mei Huang, Karim Iskander, Daniel J. Lenihan

    Published 2018
    Get full text
    Revisão
    Save to List
    Saved in:

Search Tools: